1. Home
  2. ALT

as 08-27-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Founded: 1997 Country:
United States
United States
Employees: N/A City: GAITHERSBURG
Market Cap: 292.0M IPO Year: N/A
Target Price: $17.40 AVG Volume (30 days): 2.8M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.17 EPS Growth: N/A
52 Week Low/High: $2.90 - $11.16 Next Earning Date: 08-12-2025
Revenue: $20,000 Revenue Growth: -95.11%
Revenue Growth (this year): -81.06% Revenue Growth (next year): 761880.20%

ALT Daily Stock ML Predictions

Share on Social Networks: